Q3 2025 Management View President and CEO Punit Dhillon reported that recent data from the Phase IIa CB1 study has "sharpened our focus, maintained our focus on our clinical path and strengthened our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback